Clinical Trials Browser

Interventional × Bites and Stings × durvalumab × Clear all

NCT05361395 2026-03-03

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Phase 1 Active not recruiting

Bites and Stings, Lung Neoplasms